Thymosin Alpha-1

Immune Modulating Peptideapproved_international

Also known as: Tα1, Ta1, Thymalfasin, Zadaxin

A 28-amino acid thymic peptide that modulates immune function, approved in multiple countries for hepatitis B and used as an immune enhancer in cancer and infectious disease.

Overview

Thymosin Alpha-1 (Tα1) is a naturally occurring 28-amino acid peptide originally isolated from thymosin fraction 5 of the thymus gland. It plays a critical role in immune system maturation and regulation, particularly in T-cell development and function. The synthetic version, thymalfasin (marketed as Zadaxin), is approved in over 35 countries for treatment of hepatitis B and as an immune adjuvant. Tα1 acts as an immune modulator rather than a simple stimulant — it enhances immune responses when they are suppressed and can also temper excessive inflammation. This dual action makes it valuable for immunocompromised patients, chronic viral infections, cancer immunotherapy adjunctive treatment, and potentially for immune aging (immunosenescence). During the COVID-19 pandemic, Tα1 received significant attention for its potential to improve outcomes in severe infections.

Mechanism of Action

Thymosin Alpha-1 modulates immunity through multiple pathways: (1) Activates dendritic cells via TLR2, TLR7, and TLR9, enhancing antigen presentation; (2) Promotes T-cell maturation and differentiation, particularly CD4+ and CD8+ T cells; (3) Enhances NK cell cytotoxicity; (4) Stimulates IL-2 and IFN-alpha production for antiviral defense; (5) Modulates inflammatory cytokines, reducing excessive IL-6 and TNF-alpha while boosting protective immune responses; (6) Restores immune function in immunosenescent or immunocompromised states; (7) May enhance vaccine efficacy by improving adaptive immune responses.

Molecular Formula

C129H215N33O55

Molecular Weight

3108.3 g/mol

Sequence

Ac-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn

Dosage Protocols

Dose Range

1.6mg3.2mg

Frequency

2-3 times per week

Route

subcutaneous

Cycle Length

4-12 weeks, cycled

Standard dose is 1.6mg (based on Zadaxin clinical dosing). Administered subcutaneously, typically in the abdomen. Can be cycled for ongoing immune support.

Source: Zadaxin prescribing information and clinical protocols

Side Effects

EffectSeverity
Injection site reactionmild
Fatiguemild
Muscle achesmild
Low-grade fevermild

Pros & Cons

Approved pharmaceutical product in 35+ countries with extensive clinical use history

Acts as an immune modulator, not just stimulant — balances both underactive and overactive immune states

Remarkably safe profile with minimal side effects across decades of clinical use

Broad therapeutic potential: viral infections, cancer immunotherapy, vaccine enhancement, and immunosenescence

Well-characterized mechanism of action with clear immune biomarker effects

Not FDA-approved in the US, limiting access to compounding pharmacies or research suppliers

Requires injection administration (no oral formulation available)

May be inappropriate for patients with autoimmune conditions due to immune-enhancing effects

Relatively expensive compared to other immune-support peptides

Research Studies

Legal Status

Approved in 35+ countries (Zadaxin) for hepatitis B and as an immune adjuvant. Not FDA-approved in the US but available as a compounded or research peptide. Orphan drug designation in the US for certain indications.

Related Peptides